Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.

Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL.

Cancer Res. 2019 Feb 15;79(4):875. doi: 10.1158/0008-5472.CAN-18-4087. No abstract available.

PMID:
30770370
2.

Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.

Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL.

Cancer Res. 2016 Jan 15;76(2):440-52. doi: 10.1158/0008-5472.CAN-15-1640-T. Epub 2015 Dec 16. Erratum in: Cancer Res. 2019 Feb 15;79(4):875.

3.

Notch inhibitors and their role in the treatment of triple negative breast cancer: promises and failures.

Locatelli M, Curigliano G.

Curr Opin Oncol. 2017 Nov;29(6):411-427. doi: 10.1097/CCO.0000000000000406. Review.

PMID:
28914645
4.

Notch Signaling Regulates Mitochondrial Metabolism and NF-κB Activity in Triple-Negative Breast Cancer Cells via IKKα-Dependent Non-canonical Pathways.

Hossain F, Sorrentino C, Ucar DA, Peng Y, Matossian M, Wyczechowska D, Crabtree J, Zabaleta J, Morello S, Del Valle L, Burow M, Collins-Burow B, Pannuti A, Minter LM, Golde TE, Osborne BA, Miele L.

Front Oncol. 2018 Dec 4;8:575. doi: 10.3389/fonc.2018.00575. eCollection 2018.

5.

Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.

Ibrahim SA, Gadalla R, El-Ghonaimy EA, Samir O, Mohamed HT, Hassan H, Greve B, El-Shinawi M, Mohamed MM, Götte M.

Mol Cancer. 2017 Mar 7;16(1):57. doi: 10.1186/s12943-017-0621-z.

6.

A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer.

So JY, Lin JJ, Wahler J, Liby KT, Sporn MB, Suh N.

PLoS One. 2014 Sep 17;9(9):e107616. doi: 10.1371/journal.pone.0107616. eCollection 2014.

7.

Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-κB activity via the Notch-1 pathway.

Pan H, Zhou W, He W, Liu X, Ding Q, Ling L, Zha X, Wang S.

Int J Mol Med. 2012 Aug;30(2):337-43. doi: 10.3892/ijmm.2012.990. Epub 2012 May 9.

PMID:
22580499
8.

The functional role of Notch signaling in triple-negative breast cancer.

Speiser JJ, Erşahin C, Osipo C.

Vitam Horm. 2013;93:277-306. doi: 10.1016/B978-0-12-416673-8.00013-7. Review.

PMID:
23810012
9.

Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.

Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews-Elger K, Han X, Picon-Ruiz M, Gilbert CA, Wander SA, Capobianco AJ, El-Ashry D, Slingerland JM.

EMBO Mol Med. 2013 Oct;5(10):1502-22. doi: 10.1002/emmm.201302558. Epub 2013 Aug 27.

10.

Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer.

Shan NL, Wahler J, Lee HJ, Bak MJ, Gupta SD, Maehr H, Suh N.

J Steroid Biochem Mol Biol. 2017 Oct;173:122-129. doi: 10.1016/j.jsbmb.2016.12.001. Epub 2016 Dec 5.

11.

The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer.

Thewes V, Simon R, Hlevnjak M, Schlotter M, Schroeter P, Schmidt K, Wu Y, Anzeneder T, Wang W, Windisch P, Kirchgäßner M, Melling N, Kneisel N, Büttner R, Deuschle U, Sinn HP, Schneeweiss A, Heck S, Kaulfuss S, Hess-Stumpp H, Okun JG, Sauter G, Lykkesfeldt AE, Zapatka M, Radlwimmer B, Lichter P, Tönjes M.

Oncogene. 2017 Jul 20;36(29):4124-4134. doi: 10.1038/onc.2017.32. Epub 2017 Mar 20.

PMID:
28319069
12.

Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.

Zhang S, Chung WC, Miele L, Xu K.

Cancer Biol Ther. 2014 May;15(5):633-42. doi: 10.4161/cbt.28180. Epub 2014 Feb 20.

13.

NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.

Clementz AG, Rogowski A, Pandya K, Miele L, Osipo C.

Breast Cancer Res. 2011 Jun 14;13(3):R63. doi: 10.1186/bcr2900.

14.

TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.

Xu X, Zhang L, He X, Zhang P, Sun C, Xu X, Lu Y, Li F.

Biochem Biophys Res Commun. 2018 Jul 7;502(1):160-165. doi: 10.1016/j.bbrc.2018.05.139. Epub 2018 May 24.

PMID:
29792857
15.

[Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].

Nowacka-Zawisza M, Krajewska WM.

Postepy Hig Med Dosw (Online). 2013 Nov 26;67:1090-7. Review. Polish.

16.

Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells.

Yun J, Pannuti A, Espinoza I, Zhu H, Hicks C, Zhu X, Caskey M, Rizzo P, D'Souza G, Backus K, Denning MF, Coon J, Sun M, Bresnick EH, Osipo C, Wu J, Strack PR, Tonetti DA, Miele L.

Oncogenesis. 2013 Aug 5;2:e60. doi: 10.1038/oncsis.2013.26.

17.

NF-κB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype.

Yamamoto M, Taguchi Y, Ito-Kureha T, Semba K, Yamaguchi N, Inoue J.

Nat Commun. 2013;4:2299. doi: 10.1038/ncomms3299.

PMID:
23934482
18.

The Vacuolar ATPase a2-subunit regulates Notch signaling in triple-negative breast cancer cells.

Pamarthy S, Jaiswal MK, Kulshreshtha A, Katara GK, Gilman-Sachs A, Beaman KD.

Oncotarget. 2015 Oct 27;6(33):34206-20. doi: 10.18632/oncotarget.5275.

19.

PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.

Wang K, Zhang Q, Li D, Ching K, Zhang C, Zheng X, Ozeck M, Shi S, Li X, Wang H, Rejto P, Christensen J, Olson P.

Clin Cancer Res. 2015 Mar 15;21(6):1487-96. doi: 10.1158/1078-0432.CCR-14-1348. Epub 2015 Jan 6.

20.

Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.

Liu J, Chen X, Ward T, Pegram M, Shen K.

Tumour Biol. 2016 Jul;37(7):9825-35. doi: 10.1007/s13277-015-4650-1. Epub 2016 Jan 26.

PMID:
26810188

Supplemental Content

Support Center